[go: up one dir, main page]

HK1211581A1 - Novel inhibitor compounds of phosphodiesterase type 10a 10a - Google Patents

Novel inhibitor compounds of phosphodiesterase type 10a 10a

Info

Publication number
HK1211581A1
HK1211581A1 HK15112371.7A HK15112371A HK1211581A1 HK 1211581 A1 HK1211581 A1 HK 1211581A1 HK 15112371 A HK15112371 A HK 15112371A HK 1211581 A1 HK1211581 A1 HK 1211581A1
Authority
HK
Hong Kong
Prior art keywords
inhibitor compounds
phosphodiesterase type
novel inhibitor
novel
phosphodiesterase
Prior art date
Application number
HK15112371.7A
Other languages
English (en)
Chinese (zh)
Inventor
Herv Geneste
Sean Turner
Michael Ochse
Karla Drescher
Lawence A Black
Katja Jantos
Clarissa Jakob
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of HK1211581A1 publication Critical patent/HK1211581A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK15112371.7A 2012-11-26 2015-12-16 Novel inhibitor compounds of phosphodiesterase type 10a 10a HK1211581A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261729877P 2012-11-26 2012-11-26
PCT/EP2013/074532 WO2014079995A2 (en) 2012-11-26 2013-11-25 Novel inhibitor compounds of phosphodiesterase type 10a

Publications (1)

Publication Number Publication Date
HK1211581A1 true HK1211581A1 (en) 2016-05-27

Family

ID=49681010

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112371.7A HK1211581A1 (en) 2012-11-26 2015-12-16 Novel inhibitor compounds of phosphodiesterase type 10a 10a

Country Status (16)

Country Link
US (2) US9790203B2 (xx)
EP (1) EP2922842B1 (xx)
JP (1) JP2016500091A (xx)
KR (1) KR20150088873A (xx)
CN (1) CN104995183B (xx)
AU (1) AU2013349671B2 (xx)
BR (1) BR112015012156A2 (xx)
CA (1) CA2891995A1 (xx)
ES (1) ES2639956T3 (xx)
HK (1) HK1211581A1 (xx)
IL (1) IL238739A0 (xx)
MX (1) MX2015006539A (xx)
RU (1) RU2015125306A (xx)
SG (1) SG11201504115XA (xx)
TW (1) TW201422604A (xx)
WO (1) WO2014079995A2 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11427595B2 (en) 2018-10-22 2022-08-30 Trustees Of Boston University Compositions and methods for inhibiting viral infection
GB202002926D0 (en) 2020-02-28 2020-04-15 Benevolentai Tech Limited Compositions and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3572617B2 (ja) * 1993-12-29 2004-10-06 藤沢薬品工業株式会社 ピラゾロピリジンアデノシン拮抗剤
PT1104758E (pt) * 1999-12-03 2003-12-31 Pfizer Prod Inc Derivados de acetileno como agentes anti-inflamatorios/analgesicos
US20030032579A1 (en) 2001-04-20 2003-02-13 Pfizer Inc. Therapeutic use of selective PDE10 inhibitors
US20030166476A1 (en) 2002-01-31 2003-09-04 Winemiller Mark D. Lubricating oil compositions with improved friction properties
WO2005012485A2 (en) 2003-07-31 2005-02-10 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
JP2008501776A (ja) 2004-06-07 2008-01-24 ファイザー・プロダクツ・インク 肥満に関連し、かつメタボリックシンドロームに関連する状態の治療としてのホスホジエステラーゼ10の阻害
WO2006028957A1 (en) 2004-09-03 2006-03-16 Memory Pharmaceuticals Corporation 4-substituted 4, 6-dialkoxy-cinnoline derivatives as phospodiesterase 10 inhibitors for the treatment of psychiatric or neurological syndroms
PT1841757E (pt) 2005-01-07 2010-08-31 Pfizer Prod Inc Compostos de quinolina heteroaromáticos e respectiva utilização como inibidores de pde10
JP2009504759A (ja) 2005-08-16 2009-02-05 メモリ ファーマセチカル コーポレーション ホスホジエステラーゼ10阻害剤
NL2000397C2 (nl) 2006-01-05 2007-10-30 Pfizer Prod Inc Bicyclische heteroarylverbindingen als PDE10 inhibitoren.
WO2007082546A1 (en) 2006-01-20 2007-07-26 H. Lundbeck A/S Use of tofisopam as a pde10a inhibitor
CA2635439A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Aminophthalazine derivative compounds
US20070265270A1 (en) 2006-02-21 2007-11-15 Hitchcock Stephen A Cinnoline derivatives as phosphodiesterase 10 inhibitors
MX2008010668A (es) 2006-02-21 2008-10-01 Amgen Inc Derivados de cinolina como inhibidores de fosfodiesterasa 10.
US20090023756A1 (en) 2006-02-23 2009-01-22 Pfizer Inc Substituted quinazolines as pde10 inhibitors
AU2007221049A1 (en) 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
US20070265258A1 (en) 2006-03-06 2007-11-15 Ruiping Liu Quinazoline derivatives as phosphodiesterase 10 inhibitors
CA2644850A1 (en) 2006-03-08 2007-09-13 Amgen Inc. Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors
TW200815436A (en) 2006-05-30 2008-04-01 Elbion Ag 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200817400A (en) 2006-05-30 2008-04-16 Elbion Ag Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
WO2008001182A1 (en) 2006-06-26 2008-01-03 Pfizer Products Inc. Tricyclic heteroaryl compounds as pde10 inhibitors
US20080090834A1 (en) 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
PT2057153E (pt) 2006-07-10 2012-11-14 Lundbeck & Co As H Derivados (3-aril-piperazin-1-il) de 6,7- dialcoxiquinazolina, 6,7-dialcoxiftalazina e 6,7-dialcoxiisoquinolina
WO2008020302A2 (en) 2006-08-17 2008-02-21 Pfizer Products Inc. Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
US20090062277A1 (en) 2007-08-21 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
US20090062291A1 (en) 2007-08-22 2009-03-05 Essa Hu Phosphodiesterase 10 inhibitors
US20090054434A1 (en) 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
TW200918519A (en) 2007-09-19 2009-05-01 Lundbeck & Co As H Cyanoisoquinoline
WO2009068320A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
RU2010126622A (ru) 2007-11-30 2012-01-10 УАЙТ ЭлЭлСи (US) Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10
US20090143392A1 (en) 2007-11-30 2009-06-04 Elbion Gmbh Methods of Treating Obesity and Metabolic Disorders
WO2009070583A1 (en) 2007-11-30 2009-06-04 Wyeth Pyrido[3,2-e]pyrazines, process for preparing the same, and their use as inhibitors of phosphodiesterase 10
JP2010070514A (ja) * 2008-09-19 2010-04-02 Toray Ind Inc ピラゾール誘導体及びその医薬用途
US20100120763A1 (en) 2008-11-07 2010-05-13 Wyeth Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
WO2011008597A1 (en) 2009-07-14 2011-01-20 Schering Corporation Dihydroimidazoisoquinoline derivatives useful as pde10 inhibitors
EA019673B1 (ru) 2009-10-30 2014-05-30 Янссен Фармацевтика Нв Радиоактивно меченные pde10 лиганды
TWI485151B (zh) 2009-12-17 2015-05-21 Lundbeck & Co As H 作為pde10a酵素抑制劑之雜芳香族苯基咪唑衍生物
KR101199229B1 (ko) * 2010-06-18 2012-11-08 주식회사 알파켐 플루오란센 유도체 및 이를 이용한 유기전계발광소자
CA2817385A1 (en) 2010-11-10 2012-05-18 H. Lundbeck A/S Radiolabelled phenylimidazole-based ligands
US8691821B2 (en) 2010-11-11 2014-04-08 Bristol-Myers Squibb Company Oxazolidinones as modulators of mGluR5
US20120214842A1 (en) 2011-02-18 2012-08-23 Exonhit Therapeutics Sa Methods for treating diseases of the retina
CN103159738B (zh) 2011-12-19 2016-09-07 上海泓博智源医药股份有限公司 炔基桥连的杂芳香化合物及其应用

Also Published As

Publication number Publication date
KR20150088873A (ko) 2015-08-03
BR112015012156A2 (pt) 2017-07-11
MX2015006539A (es) 2015-10-30
CN104995183B (zh) 2018-04-06
CA2891995A1 (en) 2014-05-30
IL238739A0 (en) 2015-06-30
US20180030033A1 (en) 2018-02-01
TW201422604A (zh) 2014-06-16
WO2014079995A3 (en) 2014-07-17
JP2016500091A (ja) 2016-01-07
EP2922842B1 (en) 2017-06-14
SG11201504115XA (en) 2015-07-30
AU2013349671A1 (en) 2015-05-21
AU2013349671B2 (en) 2018-03-29
ES2639956T3 (es) 2017-10-30
WO2014079995A2 (en) 2014-05-30
US9790203B2 (en) 2017-10-17
US20140148461A1 (en) 2014-05-29
RU2015125306A (ru) 2017-01-10
CN104995183A (zh) 2015-10-21
EP2922842A2 (en) 2015-09-30

Similar Documents

Publication Publication Date Title
IL263262B (en) Atr kinase inhibitor compounds, preparations containing them, their uses and methods for their preparation
SG10201605196PA (en) Novel Inhibitor Compounds Of Phosphodiesterase Type 10A
HK1201519A1 (en) Inhibitors of phosphodiesterase type 10a 10a
HK1215253A1 (zh) 作為激酶抑制劑的吡咯並嘧啶化合物
HK1211921A1 (en) Inhibitor compounds
HK1211942A1 (en) Pyrazolopyrimidine compounds as kinase inhibitors
HK1210178A1 (en) Substituted pyridopyrazines as syk inhibitors syk
HK1219273A1 (zh) 磷酸二酯酶 型的新型抑制劑化合物
HK1211024A1 (en) Inhibitors of syk syk
HK1206728A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a 10a
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201211019D0 (en) Inhibitor compounds
HK1211581A1 (en) Novel inhibitor compounds of phosphodiesterase type 10a 10a
PT2784068E (pt) Inibidor da fosfodiesterase-4 capaz de evitar os vómitos
HK1211284A1 (en) Inhibitor compounds of phosphodiesterase type 10a 10a